We are live on
!
Find out more
Federated Hermes Portfolio holdings
AUM
$69.6B
1-Year Est. Return
42.52%
This Fund
S&P 500
This Quarter
Est. Return
+1.34%
1 Year Est. Return
+42.52%
3 Year Est. Return
+132.48%
5 Year Est. Return
+152.58%
10 Year Est. Return
+652.43%
AUM
$42.2B
AUM Growth
-$1.23B
(-2.8%)
Cap. Flow
-$952M
Cap. Flow
% of AUM
-2.26%
Top 10 Holdings %
Top 10 Hldgs %
14.57%
Holding
2,171
New
150
Increased
772
Reduced
960
Closed
152
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$156M |
| 2 |
Prologis
PLD
|
+$150M |
| 3 |
Chevron
CVX
|
+$109M |
| 4 |
Qualcomm
QCOM
|
+$101M |
| 5 |
Paycom
PAYC
|
+$90.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
FUSN
Fusion Pharmaceuticals Inc. Common Shares
FUSN
|
+$230M |
| 2 |
Kimberly-Clark
KMB
|
+$160M |
| 3 |
Stanley Black & Decker
SWK
|
+$130M |
| 4 |
Paychex
PAYX
|
+$113M |
| 5 |
Dominion Energy
D
|
+$105M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.81% |
| 2 | Healthcare | 17.11% |
| 3 | Financials | 12.73% |
| 4 | Industrials | 9.87% |
| 5 | Consumer Discretionary | 9.74% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1376
Coty
COTY
$2.32B
| $369K | ﹤0.01% |
36,827
-2,652
| -7% | -$28.4K |
|
1377
Southern Copper
SCCO
$160B
| $369K | ﹤0.01% |
3,701
-1,225
| -25% | -$129K |
|
1378
CNA Financial
CNA
$13B
| $368K | ﹤0.01% |
+7,981
| New | +$354K |
|
1379
Fluence Energy
FLNC
$1.3B
| $365K | ﹤0.01% |
21,069
+1,851
| +10% | +$35.5K |
|
1380
Silgan Holdings
SLGN
$4.08B
| $361K | ﹤0.01% |
8,530
-476
| -5% | -$22.1K |
|
1381
Invitation Homes
INVH
$16.1B
| $361K | ﹤0.01% |
10,057
-7,462
| -43% | -$259K |
|
|
NXRT
1382
NexPoint Residential Trust
NXRT
$545M
| $359K | ﹤0.01% |
9,094
+359
| +4% | +$12.6K |
|
1383
GATX Corp
GATX
$6.27B
| $356K | ﹤0.01% |
2,690
-132
| -5% | -$17.4K |
|
1384
Kemper
KMPR
$1.61B
| $356K | ﹤0.01% |
6,000
-188
| -3% | -$11K |
|
1385
Assembly Biosciences
ASMB
$519M
| $348K | ﹤0.01% |
25,394
| – | – |
|
1386
Photronics
PLAB
$1.64B
| $346K | ﹤0.01% |
14,041
-6,060
| -30% | -$164K |
|
1387
Sabra Healthcare REIT
SBRA
$5.13B
| $346K | ﹤0.01% |
22,439
-1,853
| -8% | -$26.5K |
|
1388
Valaris
VAL
$5.73B
| $345K | ﹤0.01% |
4,629
-279
| -6% | -$20.2K |
|
1389
Valley National Bancorp
VLY
$7.48B
| $344K | ﹤0.01% |
49,214
-1,738
| -3% | -$12.7K |
|
1390
Travere Therapeutics
TVTX
$5.98B
| $343K | ﹤0.01% |
+41,717
| New | +$281K |
|
1391
Concentrix
CNXC
$1.78B
| $341K | ﹤0.01% |
5,394
-262
| -5% | -$15.7K |
|
1392
Spire
SR
$4.72B
| $340K | ﹤0.01% |
5,601
-288
| -5% | -$17.4K |
|
1393
Amylyx Pharmaceuticals
AMLX
$3.64B
| $340K | ﹤0.01% |
178,774
+2,791
| +2% | +$5.41K |
|
1394
General Dynamics
GD
$97.4B
| $333K | ﹤0.01% |
1,147
-38
| -3% | -$11.1K |
|
|
NSA
1395
DELISTED
National Storage Affiliates Trust
NSA
| $330K | ﹤0.01% |
8,000
-1,318
| -14% | -$49.7K |
|
1396
Envista
NVST
$4.01B
| $328K | ﹤0.01% |
19,713
-63,283
| -76% | -$1.2M |
|
1397
Provident Financial
PROV
$115M
| $323K | ﹤0.01% |
25,821
-926
| -3% | -$11.9K |
|
1398
Avery Dennison
AVY
$13.1B
| $321K | ﹤0.01% |
1,470
+532
| +57% | +$118K |
|
1399
Willis Towers Watson
WTW
$29.1B
| $321K | ﹤0.01% |
1,225
-2,168
| -64% | -$560K |
|
1400
Hilton Grand Vacations
HGV
$2.88B
| $319K | ﹤0.01% |
7,899
-877
| -10% | -$37.2K |
|
Similar funds
Federated Hermes's Q2 2024 Portfolio in Review
As of Q2 2024, Federated Hermes held 2,171 positions worth $42.2B, down 2.8% from $43.4B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Federated Hermes's Q2 2024 filing shows 150 new, 772 increased, 960 reduced and 152 closed positions. Its largest new stake was Loar Holdings: 729,296 shares worth $39M. The largest sale was Fusion Pharmaceuticals Inc. Common Shares, an estimated $230M.
By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 17% a quarter earlier, followed by Healthcare and Financials.
- Federated Hermes's largest Q2 2024 buy was Loar Holdings: 729,296 shares worth $39M.
- Federated Hermes added most to Bristol-Myers Squibb in Q2 2024, an estimated $156M increase.
- Federated Hermes's biggest Q2 2024 reduction was Kimberly-Clark, cutting an estimated $160M.
- Federated Hermes fully exited Fusion Pharmaceuticals Inc. Common Shares in Q2 2024, selling an estimated $230M.
- Federated Hermes's ten largest holdings make up 15% of its $42.2B portfolio in Q2 2024.
- Federated Hermes opened 150 new positions and closed 152 in Q2 2024.
- Federated Hermes's portfolio value fell 2.8% quarter-over-quarter to $42.2B.
Based on Federated Hermes's 13F filing for Q2 2024, filed 8 Aug 2024.